AstraZeneca (AZN) and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu (trastuzumab deruxtecan) in breast cancer.The regulatory body has now approved Enhertu as a monotherapy for treating metastatic HR-positive, HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for the therapy as the next line of treatment in the European Union (“EU”).The la ...

Group 1 - AstraZeneca achieved a remarkable 18% increase in revenue, reaching record levels in 2024 [1] - The growth in revenue was primarily driven by strong performance in key therapeutic areas [1] Group 2 - AstraZeneca is recognized as one of the pillars of the global pharmaceutical industry [1]

Signage at the AstraZeneca facility in Gaithersburg, Maryland, US, on Monday, Aug. 26, 2024. He said that leads to 4 million to 5 million deaths worldwide due to elevated cholesterol. While PCSK9 injections have helped treatment reach more patients, their use has still been "very limited," Makar said. That's due to several factors, such as challenges related to cost and access and hesitancy among some cardiologists and primary care physicians. "That's why we're really excited about our oral PCSK9," Makar sa ...

Core Insights - J&J's phase III MARIPOSA study shows that the combination of Rybrevant and Lazcluze significantly extends overall survival in patients with EGFR-mutated non-small cell lung cancer compared to AstraZeneca's Tagrisso [1][2] Study Results - At a median follow-up of 37.8 months, patients on J&J's combo therapy had a median overall survival not yet reached, while those on Tagrisso had a median overall survival of 36.7 months [2] - 56% of patients on J&J's therapy were alive at 3.5 years compared to 44% on AstraZeneca's drug, indicating a potential extension of overall survival by at least one year with J&J's combination [2] Regulatory Approvals - The MARIPOSA study achieved its primary endpoint of significant improvement in progression-free survival, leading to J&J securing approval for the Rybrevant-Lazcluze combo in the U.S. and EU last year [3] - The EMA's Committee for Medicinal Products for Human Use issued a positive opinion for a subcutaneous version of Rybrevant combined with Lazcluze, with a final decision expected later this year [6] - The FDA approved the combination of Rybrevant and standard chemotherapy for advanced NSCLC after prior therapy failure, with similar approval in the EU last year [7] Competitive Landscape - J&J aims to position the Rybrevant-Lazcluze combo as the new standard of care against AstraZeneca's Tagrisso, which currently holds a significant market position due to its convenience as a once-daily pill [4] - J&J's regimen requires intravenous infusions, which may limit its adoption compared to Tagrisso [4] Future Developments - A key step for J&J is obtaining FDA approval for a subcutaneous version of Rybrevant to reduce administration time, following a previous rejection due to manufacturing concerns [5] - J&J is also exploring Rybrevant in other NSCLC settings, evaluating it in various clinical studies as monotherapy or in combination with other drugs [9]

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registrant ...

Group 1 - Recent policies and upgrades in the biopharmaceutical industry in China have led multiple multinational pharmaceutical companies to increase their investments in the country [1][2] - Pfizer has officially opened its third research and development center in China, aiming to accelerate the global synchronized development of innovative drugs to meet the growing demand from an aging population [1] - AstraZeneca announced a $2.5 billion investment to establish a global strategic R&D center in China, which will be its second in the country and sixth globally [1] Group 2 - AstraZeneca has also revealed several R&D collaborations with Chinese biotech firms, including a strategic investment of $105 million in Hengrui Medicine to co-develop next-generation multi-specific antibody therapies [2] - Other multinational companies like Eli Lilly and Takeda have also expressed intentions to strengthen their presence in the Chinese market, with Eli Lilly reporting a 9% growth in its business in China for 2024 [2] - The Chinese government's ongoing high-level opening-up policies and measures to simplify approval processes are expected to release policy dividends, providing ample growth opportunities for multinational pharmaceutical companies [2][3] Group 3 - The talent and R&D environment in China are highly attractive to multinational pharmaceutical companies, with the digital healthcare system and innovative industry clusters offering broader market space for development [3]

The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy, resulting in heart failure.AstraZeneca Plc‘s AZN Alexion will be responsible ...

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Astrazeneca (AZN), and highlights the potential misalignment of interests between brokerage analysts and retail investors [1][5][10]. Brokerage Recommendations - Astrazeneca has an average brokerage recommendation (ABR) of 1.38, indicating a position between Strong Buy and Buy, based on recommendations from 16 brokerage firms [2]. - Out of the 16 recommendations, 13 are Strong Buy, accounting for 81.3% of all recommendations [2]. Limitations of Brokerage Recommendations - Solely relying on brokerage recommendations for investment decisions may not be advisable, as studies suggest they have limited success in guiding investors towards stocks with high price appreciation potential [5]. - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, with five "Strong Buy" recommendations for every "Strong Sell" [6][10]. Zacks Rank Comparison - Zacks Rank, a proprietary stock rating tool, categorizes stocks from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) and is based on earnings estimate revisions, making it a more effective indicator of near-term stock performance [8][11]. - The Zacks Rank is updated more frequently than the ABR, reflecting timely changes in earnings estimates, which are crucial for predicting future stock prices [12]. Current Earnings Outlook for Astrazeneca - The Zacks Consensus Estimate for Astrazeneca's current year earnings has decreased by 0.6% over the past month to $4.49, indicating growing pessimism among analysts regarding the company's earnings prospects [13]. - This decline in earnings estimates has resulted in a Zacks Rank 4 (Sell) for Astrazeneca, suggesting caution despite the Buy-equivalent ABR [14].

Core Insights - Lunit is set to present a deep learning study on predicting EGFR mutations in non-small cell lung cancer (NSCLC) at the AACR Annual Meeting 2025, showcasing the Lunit SCOPE Genotype Predictor in collaboration with AstraZeneca [1][2] Group 1: Study Details - The study utilizes the largest and most diverse training dataset to date, comprising over 12,000 pathology slides, including more than 4,500 EGFR-mutated and over 7,500 wild-type samples from NSCLC patients across multiple countries [3] - The AI model demonstrated consistent performance across various clinical variables, including specimen types, EGFR mutation subtypes, slide scanners, and scan magnifications, indicating its potential for real-world application [4] Group 2: Industry Impact - The collaboration aims to enhance the efficiency of EGFR mutation testing, which is critical for determining treatment options for NSCLC patients, addressing logistical and resource constraints that have previously limited testing [3][5] - The successful application of AI in this context could enable clinicians to prioritize molecular testing, ensuring timely access to targeted therapies for patients [5] Group 3: Company Background - Lunit, founded in 2013, focuses on AI-powered medical image analytics and biomarker analysis to improve cancer diagnosis and treatment, with its FDA-cleared Lunit INSIGHT suite serving over 4,800 medical institutions globally [7] - The company has a strong presence in the medical community, with clinical studies published in prestigious journals and presented at major global conferences [7]

中国发展高层论坛亮点多！在中国加速布局研发中心成外企投资"新潮流"→ 高清 倍速 00:00 03:07 （央视财经《天下财经》）近年来，中国显著增加的创新实力成为吸引外资的强大磁力。如何在开放合作中实现科技创新与产业创新的深度融合，并为全球 经济注入新的动力，成为论坛上与会嘉宾热议的话题。 值得注意的是，在生产之外，在华设立研发中心，与国内企业联合开展技术攻关，逐渐成为外商投资的"新潮流"。近日，阿斯利康宣布将在北京投资25亿美 元，建立第六个全球战略研发中心以及高标准产业化项目，加强其在生物医药领域的研发创新。 工业和信息化部党组书记李乐成在论坛上表示，中国深入实施创新驱动发展战略，坚持以科技创新引领产业创新，创新能力持续提升，创新对新型工业化的 驱动更加有力，产业科技创新这一"关键变量"正加速转化为新质生产力的"最大增量"。目前，外商累计在华投资设立的企业数量超过123.9万家，我国制造 业的31个大类和548个小类都有外商投资。 工业和信息化部党组书记李乐成：推动科技创新和产业创新深度融合，不是中国的独奏曲，而是世界的大合唱。中国具有完备的产业体系，丰富的应用场 景，超大规模的市场，数量庞大的人才队伍 ...